Cancer Research UK

Faron-supported research published in Theranostics identified secreted Clever-1 (sClever-1) as a key immunosuppressive mediator that impairs T-cell responses and contributes to anti-PD-1 therapy resistance in cancer patients.

Researchers at The Institute of Cancer Research, London, have demonstrated that combining tazemetostat with DOT1L inhibitor pinometostat can overcome treatment resistance in B-cell lymphoma patients.

The NHS will be the first health system in Europe to trial histotripsy, a non-invasive ultrasound technology that destroys liver tumors using sound waves to create "bubble clouds" that pulverize cancer cells.

The BRAID trial found that contrast-enhanced mammography and abbreviated MRI could detect up to 3,500 additional breast cancers annually in women with dense breasts.

Cambridge researchers have developed a promising combination therapy using venetoclax and inobrodib that effectively targets B-cell acute lymphoblastic leukemia (B-ALL), potentially reducing the need for toxic chemotherapy.

A phase 3 clinical trial led by the University of Leeds demonstrated that a second stem cell transplant followed by ixazomib maintenance therapy extends myeloma remission by seven months compared to standard care.

A groundbreaking clinical trial led by Addenbrooke's Hospital demonstrates 100% three-year survival rate for patients with BRCA-mutated breast cancer when treated with olaparib plus chemotherapy before surgery.

Research presented at the European Congress on Obesity suggests weight loss injections may reduce obesity-related cancer risk by nearly 50%, potentially through anti-inflammatory mechanisms beyond simple weight reduction.

The phase 2 PLATO-ACT4 trial demonstrated that reduced-dose intensity-modulated radiotherapy (IMRT) achieved comparable complete clinical response rates to standard dosing in early-stage anal cancer patients.

A groundbreaking UK trial has developed a highly sensitive bone marrow test that can detect returning Acute Myeloid Leukemia up to three months earlier than standard blood tests, potentially doubling survival rates for some patients.